Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reporting times for onc year end

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Mar 01, 2024 2:34pm

185 Views

Post# 35909963

RE:Reporting times for onc year end

Granted & understood. Onc has until end of March under existing rules to report the yr end & Q4.
However +/- a few days have always reported first week of March.
Many strange events going on. Even for Onc type strange.
i do hope is delayed holing off on some great news.
They know full well questions need to be answered regarding both MBc & Pancreatic phase 3.
A partner, buyout or restructuring is needed to fund even one of the two trials.
Could the delay be absolutely nothing? Possible.
Being an optomist I assume lots of talk in the background, delaing with the answers to needed questions.
As always, time will tell.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities